MYCO-006 is an

MDMA 3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy (tablet form), and molly (crystal form), is an empathogen–entactogenic drug with stimulant and minor Psychedelic drug, psychedelic properties. In studies, it has been used ...

-like

entactogen Entactogens, also known as empathogens or connectogens, are a class of psychoactive drugs that induce the production of experiences of emotional communion, oneness, connectedness, emotional openness—that is, empathy—as particularly observe ...

that is under development for the treatment of

psychiatric disorder A mental disorder, also referred to as a mental illness, a mental health condition, or a psychiatric disability, is a behavioral or mental pattern that causes significant distress or impairment of personal functioning. A mental disorder is ...

s. It is a short-acting and fast-onset MDMA analogue. Based on

animal studies Animal studies is a recently recognised field in which animals are studied in a variety of cross-disciplinary ways. Scholars who engage in animal studies may be formally trained in a number of diverse fields, including art history, anthropology ...

, it is predicted that MYCO-006 will have a duration of 1 to 2hours, about one-third the 6- to 8-hour duration of MDMA, and to onset 4times as fast as MDMA. MYCO-006 is being developed by

Mydecine Mydecine Innovations Group, or simply Mydecine, is an United States, American and Canada, Canadian pharmaceutical company that is developing psychedelic drug, psychedelics and entactogens as medicines. In August 2022, it was reported that Mydecin ...

. As of February 2024, it is in

preclinical research In drug development, preclinical development (also termed preclinical studies or nonclinical studies) is a stage of research that begins before clinical trials (testing in humans) and during which important feasibility, iterative testing and dr ...

. The

chemical structure A chemical structure of a molecule is a spatial arrangement of its atoms and their chemical bonds. Its determination includes a chemist's specifying the molecular geometry and, when feasible and necessary, the electronic structure of the target m ...

of MYCO-006 does not yet appear to have been disclosed. and were described in Mydecine's patent for short-acting MDMA analogues.

References

Drugs with undisclosed chemical structures Entactogens Experimental entactogens Monoamine releasing agents {{Psychoactive-stub

See also

References